We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current RGLS market cap is 47.52M. The company's latest EPS is USD -1.4853 and P/E is -1.55.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -7.56M | -6.93M | -7.37M | -7.32M | -8.13M |
| Net Income | -7.55M | -6.8M | -7.14M | -7.01M | -7.82M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 6.83M | 10.01M | 0 | 0 | 0 |
| Operating Income | -16.83M | -14.16M | -27.82M | -28.24M | -31.11M |
| Net Income | -18.59M | -15.73M | -27.81M | -28.32M | -30.04M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 52.13M | 46.72M | 37.02M | 43.65M | 37.75M |
| Total Liabilities | 12.46M | 13.43M | 10.42M | 9.65M | 9.49M |
| Total Equity | 39.67M | 33.29M | 26.6M | 34M | 28.26M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 42.08M | 37.6M | 68.45M | 46.72M | 30.75M |
| Total Liabilities | 22.07M | 11.58M | 13.5M | 13.43M | 9.56M |
| Total Equity | 20.02M | 26.03M | 54.96M | 33.29M | 21.19M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -19.27M | -25.53M | -8.11M | -14.37M | -20.64M |
| Investing | -25.59M | -15.12M | 15M | 15M | 9.56M |
| Financing | 4.49M | 4.49M | -805k | 12.4M | 12.69M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -19.82M | -12.54M | -24.13M | -25.53M | -26.77M |
| Investing | 74k | -11k | -251k | -15.12M | 14.49M |
| Financing | 39.93M | 9.51M | 53.74M | 4.49M | 11.82M |
| Market Cap | 47.52M |
| Price to Earnings Ratio | -1.55 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 1.96 |
| Price to Book Ratio | 2.2 |
| Dividend Yield | - |
| Shares Outstanding | 20.22M |
| Average Volume (1 week) | 142.03k |
| Average Volume (1 Month) | 275.34k |
| 52 Week Change | 78.03% |
| 52 Week High | 3.78 |
| 52 Week Low | 1.08 |
| Spread (Intraday) | 0.14 (5.81%) |
| Company Name | Regulus Therapeutics Inc |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https://www.regulusrx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
